Identifying a neurobiologic basis for drug therapy in TMDs

Journal of the American Dental Association

Volumn 127, Issue 5, 1996, Pages 581-593

  Denucci, Donald J ^a,b   Dionne, Raymond A ^d   Dubner, Ronaud ^b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c Dental School   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CENTRAL MUSCLE RELAXANT; CENTRAL NERVOUS SYSTEM AGENTS; CORTICOSTEROID; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; DEPRESSION; FACE PAIN; HUMAN; INJURY; MYOFASCIAL PAIN; PATHOPHYSIOLOGY; REVIEW; SPINAL GANGLION;

ADRENAL CORTEX HORMONES; ANALGESICS, OPIOID; ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; CENTRAL NERVOUS SYSTEM AGENTS; CHRONIC DISEASE; DEPRESSION; FACIAL PAIN; GANGLIA, SPINAL; HUMANS; KIDNEY FAILURE, CHRONIC; MUSCLE RELAXANTS, CENTRAL; TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME;

EID: 0030140086     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.1996.0270     Document Type: Article

References (80)

1. McNeill C. Craniomandibular (TMJ) disorders - the state of the art. Part II: accepted diagnosis and treatment modalities. J Prosthet Dent 1983;49(3):393-7.
2. Travell JG, Simmons RG. Myofascial trigger point manual. Baltimore: Williams & Wilkens; 1993:165-281.
3. Danzig W, May S, McNeill C, et al. Effect of an anesthetic injected into the temporomandibular joint space in patients with TMD. J Craniomandib Disord 1992;6(4):288-95.
4. McNeill C, ed. Temporomandibular disorders: guidelines for classification, assessment, and management/The American Academy of Orofacial Pain. 2nd ed. Carol Stream, Ill.: Quintessence; 1993:27-38.
5. Buckingham RB, Braun T, Harinstein DA, et al. Temporomandibular joint dysfunction syndrome: a close association with systemic joint laxity (the hypermobile joint syndrome). Oral Surg Oral Med Oral Pathol 1991;72(5):514-9.
6. Klippel JH, Koopman WJ, eds. Primer on the rheumatologic diseases. 10th ed. Atlanta: Arthritis Foundation; 1993.
7. Turk DC, Rudy TE. The robustness of an empirically derived taxonomy of chronic pain patients. Pain 1990;43(1):27-35.
8. Dubner R, Fricton JR, eds. Orofacial pain and temporomandibular disorders. Vol. 21. New York: Raven Press; 1995:61-71.
9. Gracely R, Lynch SA, Bennett GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 1992;51:175-94.
10. Koltzenburg M, Torebjork HE, Wahren LK. Nociceptor modulated central plasticity causes mechanical hyperalgesia in chronic neuropathic and acute chemogenic pain. Brain 1994;117:579-91.
11. Dubner R, Ruda MA. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci 1992;15:96-103.
12. Cervero F. Proceedings of the Vth World Congress on Pain, Pain Research, and Clinical Management. Vol. 3. Amsterdam: Elsevier; 1988.
13. Ness TJ, Gebhart GF. Visceral pain: a review of experimental studies. Pain 1990; 41:167-234.
14. Wall PD. The prevention of postoperative pain. Pain 1988;33:289-90.
15. Tverskoy M, Cozacov C, Ayache M, et al. Postoperative pain after inguinal herniorrhaphy with different types of anesthesia. Anesth Analg 1990;79:29-35.
16. Fassenbender HG. Pathology of rheumatic diseases. New York: Springer-Verlag; 1975.
17. Goss AN, Speculand DB, Hallet E. Diagnosis of temporomandibular joint pain in patients seen at a pain clinic. J Oral Maxillofac Surg 1985;43:110-4.
18. Okeson JP, Moody PM, Kemper JT, et al. Evaluation of occlusal splint therapy and relaxation procedures in patients with temporomandibular disorders. JADA 1983;107(3):420-4.
19. Greene CS. The fallacies of clinical success in dentistry. J Oral Med 1976;31:82-5.
20. Greene CS, Laskin DM. Splint therapy for the myofascial pain-dysfunction syndrome (MPD): a comparative study. JADA 1972; 84:624-8.
21. Laskin DM, Greene CS. Influence of the doctor-patient relationship on placebo therapy for patients with myofascial pain-dysfunction (MPD) syndrome. JADA 1972;85:892-4.
22. Goodman P, Greene CS, Laskin DM. Response of patients with myofascial pain-dysfunction syndrome to mock equilibration. JADA 1976;92:755-8.
23. Magnusson T, Egermark-Eriksson I, Carlsson GE. Five year longitudinal study of signs and symptoms of mandibular dysfunction in adolescents. J Craniomandibular Pract 1986;4:338-43.
24. Green CS, Olson RE, Laskin DM. Psychological factors in the etiology, progression, and treatment of MPD syndrome. JADA 1982;105(3):443-8.
25. Moody PM, Kemper JT, Okeson JP, Calhoun TC, Parker MW. Recent life changes and myofascial pain syndrome. J Prosthet Dent 1982;48(3):328-30.
26. Speculand B, Goss AN, Hughes A, Spence ND. Temporo-mandibular joint dysfunction: pain and illness behaviour. Pain 1983;17(2):139-50.
27. Greene CS, Laskin DM. Long term evaluation of conservative treatment for myofascial pain-dysfunction syndrome. JADA 1974; 89:1365-8.
28. McDonald JS, Phero JC. Evaluation of chronic pain conditions of the head and neck. New York: Elsevier; 1991.
29. Magni G. The use of antidepressants in the treatment of chronic pain: a review of the current evidence. Drugs 1991;42(5):730-48.
30. Onhegna P, Van Houdenhove B. Antidepressant-induced analgesia in chronic nonmalignant pain: a meta analysis of 39 placebo-controlled studies. Pain 1992;49:205-19.
31. Egbunike IG, Chaffee BJ. Antidepressants in the management of chronic pain syndromes. Pharmacol Ther 1990;10:262-70.
32. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-96.
33. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:1250-6.
34. Kishore-Kumar R, Schafer SC, Lawlor B, Murphy DL, Max MB. Single doses of serotonin agonists buspirone and m-chlorophenlpiperazine do not relieve neuropathic pain. Pain 1989;37:223-7.
35. Ziegler D, Lynch SA, Muir J, Benjamin J, Max MB. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992;48:403-8.
36. Sharav Y, Singer E, Schmidt E, Dionne RA, Dubner R. The analgesic effect of amitriptyline on chronic facial pain. Pain 1987;31:199-209.
37. Baldessari RJ. Drugs in the treatment of psychiatric disorders. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The pharmocologic basis of therapeutics. 7th ed. New York: MacMillan; 1985:419.
38. McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. Anesth Analg 1993;47:646-52.
39. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia 1993;48:281-5.
40. Zitman FG, Linssen AC, Edelbroek PM, Stijnen T. Low dose amitriptyline in chronic pain: the gain is modest. Pain 1990;42:35-42.
41. Lascelles RG. Atypical facial pain and depression. Br J Psychiatry 1966;112:651-9.
42. Feinmann C. Psychogenic facial pain: presentation and treatment. J Psychosom Res 1983;27(5):403-10.
43. King SA, Strain JJ. Benzodiazepine use by chronic pain patients. Clin J Pain 1990; 6:143-7.
44. Harkins S, Linford J, Cohen J, Kramer T, Cueva L. Administration of clonazepam in the treatment of TMD and associated myofascial pain: a double-blind pilot study. J Craniomandib Disord 1991;5(3):179-86.
45. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. Arthritis Rheum 1991;34:552-60.
46. Singer EJ, Sharav Y, Schmidt E, Dionne RA, Dubner R. The efficacy of diazepam and ibuprofen in the treatment of chronic myofascial pain. Pain 1987;31:183-5.
47. Dellemijn PL, Fields HL. Do benzodiazepines have a role in chronic pain management? Pain 1994;56:137-52.
48. Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm 1980;37:131-2.
49. Schwartz L, Kutscher AH, Yavelow I, Cobin HP, Brod MS. Carisoprodol in the management of temporomandibular joint pain and dysfunction: a preliminary investigation. Ann N Y Acad Sci 1960;86:245-9.
50. Gallardo F, Molgo J, Miyazaki C, Rossi E. Carisoprodol in the treatment of myofascial pain-dysfunction syndrome. J Oral Surg 1975;33:655-8.
51. Bercel NA. Cyclobenzaprine in the treatment of skeletal muscle spasm in osteoarthritis of the cervical and lumbar spine. Curr Ther Res Clin Exp 1977;22:462-8.
52. Brown BR, Womble J. Cyclobenzaprine in intractable pain syndromes with muscle spasm. JAMA 1978;240:1151-2.
53. Basmajian JV. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in the lumber region and neck. Arch Phys Med Rehabil 1978;59:58-63.
54. Truelove EL. The chemotherapeutic management of chronic and persistent orofacial pain. Dent Clin North Am 1994;38(4):669-88.
55. Dworkin SF, Truelove EL, Bonica JJ, Sola A. Facial and head pain caused by myofascial and temporomandibular disorders. In: Bonica JJ, ed. The management of pain. Philadelphia: Lea & Febiger; 1990:727-45.
56. Gordon SM, Montgomery MT, Jones D. Comparative efficacy of piroxicam versus placebo for temporomandibular pain (Abstract). J Dent Res 1990;69:218.
57. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case controlled study. Gut 1991;32:730-4.
58. Kaufman DW, Kelly JP, Sheehan JE, et al. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993;53:485-94.
59. Laporte JR, Carne X Vidai X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991;337:85-9.
60. Gabriel SE, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal antunflammatory drugs. Ann Int Med 1991;115:787-96.
61. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72.
62. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-98.
63. Perneger TW, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetominophen, aspirin, and non-steroidal antiinflammatory agents. N Engl J Med 1994;331:1675-9.
64. Kopp S, Akerman S, Nilner M. Short-term effects of intra-articular sodium hyaluronate, glucocorticoid, and saline injections on rheumatoid arthritis of the temporomandibular joint. J Craniomandib Disord 1991;5(4):231-8.
65. Wenneberg B, Kopp S, Grondahl HG. Long-term effect of intra-articular injections of a glucocorticosteroid into the TMJ: a clinical and radiographic 8-year follow-up. J Craniomandib Disord 1991;5(1):11-8.
66. Kopp S, Wenneberg B. Effects of occlusal treatment and intra-articular injections on temporomandibular joint pain and dysfunction. Acta Odontol Scand 1981;39:87-96.
67. Aggarwal S, Kumar A. A cortisone-wrecked and bony ankylosed TMJ (letter). Plast Reconstr Surg 1986;83:1084-5.
68. Acton CH. Steroid-induced anterior open bite: case report. Aust Dent J 1986; 31:455-8.
69. Reid KI, Dionne RA, Sicard-Rosenbaum L, Lord D, Dubner R. Evaluation of iontophoretically applied dexamethasone for painful pathologic temporomandibular joints. Oral Surg Oral Med Oral Pathol 1994;77:605-9.
70. Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991;41:326-44.
71. Halpern LM. Analgesic and anti-inflammatory medications. In: Tollison CD, ed. Handbook of chronic pain management. Baltimore: Williams & Wilkens; 1989:54-68.
72. Gildenberg PL, DeVaul RA. The chronic pain patient. Basel, Switzerland: Karger; 1985:97.
73. Laskin DM. Changing concepts in the management of chronic pain (editorial). J Oral Maxillofac Surg 1995;53:497.
74. Schug SA, Merry AF, Acland RH. Treatment principles for the use of opioids in pain of nonmalignant origin. Drugs 1991;42:2.
75. Reidenberg MM, Portenoy RK. The need for an open mind about the treatment of chronic nonmalignant pain (commentary). Clin Pharmacol Ther 1994;55:367-9.
76. France RD, Urban BJ, Keefe FJ. Long-term use of narcotic analgesics in chronic pain. Soc Sci Med 1984;19:1379-82.
77. Tennant FS, Robinson D, Sagherian A, Seecof R. Chronic opioid treatment of intractable non-malignant pain. NIDA Res Monogr 1988;81:174-80.
78. Zenz M, Strumpf M, Tryba M. Long-term use of opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992;7:69-77.
79. Portenoy RK. Chronic opioid therapy for nonmalignant pain: from models to practice. APS Journal 1992;1:285-8.
80. Portenoy RK. Opioid therapy for chronic nonmalignant pain: current status. In: Fields HL, Liebeskind JC, eds. Progress in pain research and management. Vol 1. Seattle: ISAP Press; 1994:247-87.